BioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 52-Week High – Here’s What Happened

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reached a new 52-week high during trading on Wednesday . The stock traded as high as $9.00 and last traded at $8.99, with a volume of 3116135 shares traded. The stock had previously closed at $8.63.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Needham & Company LLC raised their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Barclays boosted their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. JMP Securities reissued a “market outperform” rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Finally, Evercore ISI lifted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $15.50.

BioCryst Pharmaceuticals Stock Performance

The stock has a market capitalization of $1.83 billion, a P/E ratio of -14.46 and a beta of 1.75. The business has a 50 day simple moving average of $7.83 and a 200-day simple moving average of $7.76.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Venturi Wealth Management LLC acquired a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at about $46,000. R Squared Ltd bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth approximately $48,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares during the last quarter. KBC Group NV boosted its holdings in BioCryst Pharmaceuticals by 80.1% during the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after buying an additional 4,537 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in BioCryst Pharmaceuticals in the fourth quarter worth approximately $80,000. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.